Trial Profile
Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Dec 2015 New trial record